Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer
Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer
复制标题
Ephrin-A2 的组织和循环水平对前列腺癌的诊断和预后价值
DOI：
10.1007/s13277-015-4398-7
复制
发表时间：
2016-04-01
期刊：
影响因子：
--
通讯作者：
Guan, Ming
中科院分区：
文献类型：
--
作者：
Li, Shibao;Wu, Zhiyuan;Guan, Ming
Ephrin-A2是Eph/ephrin家族的成员，与肿瘤发生和肿瘤进展相关。本研究旨在评估血清和组织中Ephrin-A2水平在前列腺癌（PCa）治疗中的诊断和预后价值。通过定量逆转录-PCR（qRT-PCR）、免疫组织化学、酶联免疫吸附试验和蛋白质印迹法检测了145例冷冻前列腺组织、55例石蜡包埋前列腺组织、88例血清样本和7种前列腺细胞系（RWPE-1、LNCaP、LNCaP-LN 3、PC-3、PC-3 M、PC-3 M-LN 4和DU 145）。在良性前列腺增生（BPH）、前列腺癌（PCa）和5种前列腺癌细胞系中检测到8.6%（5/58）的Ephrin-A2 mRNA或蛋白的诱导表达。Ephrin-A2在BPH和PCa中的阳性率分别为6.7%（1/15）和62.5%（25/40）。因此，血清Ephrin-A2在PCa患者中显著高于BPH患者和对照组（P< 0.001）。Ephrin-A2在Gleason评分升高或T3-T4分期的肿瘤患者中表达更高。Ephrin-A2表达与Ki-67表达在PCa患者中相关，无论是在基因水平还是蛋白水平。我们的数据表明，Ephrin-A2是一个潜在的诊断和预后生物标志物和一个有前途的分子治疗靶点，以减轻前列腺癌的进展。
Ephrin-A2, a member of the Eph/ephrin family, is associated with tumorigenesis and tumor progression. This study aimed to assess the diagnostic and prognostic value of both serum and tissue levels of Ephrin-A2 in prostate cancer (PCa) management. One hundred and forty-five frozen prostate tissues, 55 paraffin-embedded prostate tissues, 88 serum samples, and seven prostate cell lines (RWPE-1, LNCaP, LNCaP-LN3, PC-3, PC-3M, PC-3M-LN4, and DU145) were examined via quantitative reverse transcription-PCR (qRT-PCR), immunohistochemistry, enzyme-linked immunosorbent assay, and western blotting. Induced Ephrin-A2 messenger RNA (mRNA) or protein expression was detected in 8.6 % (5/58) benign prostatic hyperplasia (BPH), 59.8 % (52/87) PCa, and five prostate cancer cell lines. Ephrin-A2 immunostaining was present in 6.7 % (1/15) patients with BPHs and 62.5 % (25/40) clinically localized PCa. Accordingly, serum Ephrin-A2 was significantly higher in PCa patients compared to those in the BPH patients and controls (P< 0.001). The expression of Ephrin-A2 was higher in tumor patients with an elevated Gleason score or T3–T4 staging. Ephrin-A2 expression was correlated with Ki-67 expression in PCa patients, both at the gene scale and protein level. Our data indicate that Ephrin-A2 is a potential diagnostic and prognostic biomarker and a promising molecular therapeutic target to attenuate prostate cancer progression.